CompletedPhase 3NCT00278954
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
Studying Primary immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bio Products Laboratory
- Principal Investigator
- Melvin Berger, MDRainbow Babies & Children's Hospital, Cleveland, Ohio
- Intervention
- Gammaplex (Intravenous immunoglobulin)(biological)
- Enrollment
- 50 enrolled
- Eligibility
- 3 years · All sexes
- Timeline
- 2006 – 2007
Study locations (7)
- Allergy Associates of the Palm Beaches, North Palm Beach, Florida, United States
- Family Allergy and Asthma Center PC, Atlanta, Georgia, United States
- Rush University Medical Centre, University Consultants in Allergy & Immunology, Chicago, Illinois, United States
- Childrens Hospital at Buffalo, Allergy Division, Buffalo, New York, United States
- Allergy, Asthma & Immunology Clinic, P.A., Irving, Texas, United States
- UCLA Medical Centre, Irving, Texas, United States
- University of Washington School of Medicine, Dept. of Pediatrics, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00278954 on ClinicalTrials.govOther trials for Primary immunodeficiency
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE4NCT07076446An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CSL Behring
- RECRUITINGPHASE1, PHASE2NCT06839456Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCTChildren's Hospital of Philadelphia
- RECRUITINGNCT06565078A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary ImmunodeficiencyTakeda
- RECRUITINGNANCT07261891Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disordersprof. dr. Rik Schrijvers
- ENROLLING BY INVITATIONNCT06144229Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening AccuraciesUniversity of California, Los Angeles
- ACTIVE NOT RECRUITINGPHASE2NCT06549114Leniolisib for Immune Dysregulation in PIDsPharming Technologies B.V.
- RECRUITINGNANCT06659588Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral DeficiencyAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07004803Virtual Reality on Pain and Fear Levels of Children With Primary ImmunodeficiencyDr. Hatice Dönmez